Amlodipine Besylate/Atorvastatin Calcium Hydrate

Tier C — Watch / trade

Pfizer Inc.

Originator

2004

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：VDCCs, HMGCR

Brand：Caduet

Indications (approved)：Hyperlipoproteinaemia type II, Hypercholesterolaemia, Hypertension, Angina pectoris, Hyperlipidaemia, Coronary artery disease, Coronary artery lesion

Regional status

Approved

2004-01-30

China

Approved

2008-04-03

Japan

Approved

2009-07-07

Factories producing this API15

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

15 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Amlodipine Besylate/Atorvastatin Calcium Hydrate?

Approved indications include: Hyperlipoproteinaemia type II, Hypercholesterolaemia, Hypertension, Angina pectoris, Hyperlipidaemia, Coronary artery disease, Coronary artery lesion.

When does the Amlodipine Besylate/Atorvastatin Calcium Hydrate patent expire?

No public expiry year is available for Amlodipine Besylate/Atorvastatin Calcium Hydrate yet; this page updates once verified.

How do I get a quote for Amlodipine Besylate/Atorvastatin Calcium Hydrate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27